Table 3 Different dose of tenecteplase vs alteplase for stroke outcomes: results from a network meta-analysis

Recanalization

1.88 (0.89–3.97)

–

1.37 (0.99–1.89)

–

1.37 (0.71–2.64)

–

Early neurological improvement

1.38 (0.89–2.14)

1.76 (0.92–3.38)

1.52 (1.13–2.05)

1.20 (0.63–2.51)

1.07 (0.84–1.35)

1.18 (0.28–4.97)

Modified Rankin scale 0–1 at 90 days　

0.93 (0.63–1.37)

1.24 (0.57–2.70)

1.19 (1.03–1.37)

1.15 (0.60–2.19)

0.91 (0.73–1.14)

1.74 (0.50–6.01)

Modified Rankin scale 0–2 at 90 days　

0.87 (0.50–1.52)

1.33 (0.43–4.10)

1.21 (1.05–1.39)

0.96 (0.47–1.96)

0.79 (0.61–1.02)

–

Any intracranial hemorrhage

0.77 (0.43–1.39)

0.98 (0.45–2.09)

0.89 (0.71–1.11)

1.30 (0.47–3.61)

1.44 (1.00–2.09)

2.04 (0.55–7.63)

Symptomatic intracranial hemorrhage

1.29 (0.47–3.58)

0.52 (0.15–1.88)

0.93 (0.60–1.44)

1.06 (0.16–6.98)

2.35 (1.19–4.64)

–

Mortality

0.81 (0.40–1.67)

1.99 (0.55–2.09)

0.78 (0.64–0.96)

0.84 (0.27–2.61)

1.26 (0.85–1.87)

1.15 (0.20–6.64)